TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
7.50
-0.27 (-3.47%)
At close: 4:02PM EDT

7.38 -0.12 (-1.60%)
After hours: 5:28PM EDT

Stock chart is not supported by your current browser
Previous Close7.77
Open7.66
Bid7.48 x 4000
Ask7.48 x 3000
Day's Range7.41 - 7.88
52 Week Range6.07 - 24.47
Volume19,799,744
Avg. Volume20,501,292
Market Cap8.665B
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-3.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est9.26
Trade prices are not sourced from all markets
  • Bloomberg

    Settling Opioid Suits Probably Won’t End the Crisis

    (Bloomberg Opinion) -- Imagine you’re the chief executive officer of a large pharmaceutical corporation with an important drug that’s under attack. More than 2,500 lawsuits have been filed against your company. The plaintiffs aren’t individuals, though, they’re governments — counties, cities and states. And some of the biggest names in the plaintiffs’ bar have agreed to represent these entities, lawyers like Joe Rice, whose firm was said to have earned $1 billion for helping to bring the tobacco companies to heel in the 1990s.You know you’ve got some incriminating-sounding documents in your corporate files — what company doesn’t? — but you also know that the Food and Drug Administration approved your drug. Patients crushed it and snorted it — something that was never intended. And you’re convinced that the plaintiffs are pushing the envelope with the public nuisance laws they are relying on to bring these cases. Yes, your company will probably lose at trial, but you think you have a good chance to win on appeal.Then you look at the army arrayed against you, and it hits you: You’re never going to be able to litigate your way out of this. It’s not just that there are 2,500 lawsuits or that they are being brought by governments. It is what that represents. Government exists to serve the interests of the people, and the people are saying that your company participated in something that inflicted tremendous damage on the country. Hundreds of thousands of people have died. And your company needs to be punished.At this point, you pick up the phone, call your opponents and say, “How much do we need to pay to settle this?”I am obviously not privy to the thinking of the CEOs of the various companies facing opioid lawsuits. But given the news of the last few days, I imagine that their thought process was not too far from what I just described. On Tuesday, the Wall Street Journal reported that three of the distributors being sued — McKesson Corp., Cardinal Health Inc., and AmerisourceBergen Corp. — have offered to pay $18 billion over 18 years to settle their cases. This news leaked less than a week before the start of a big opioid trial in Cleveland, in which the three companies are among the defendants.The next day, Bloomberg News reported that Johnson & Johnson was offering $4 billion to end the litigation, and Teva Pharmaceutical Industries Inc. was proposing to give away $15 billion worth of generic drugs to be freed of the lawsuits. On Thursday, the New York Times reported that the five companies and the states had agreed on the outlines of a settlement that would cost the companies $50 billion.And of course, Purdue Pharma Inc. had already waved the white flag, with a bankruptcy filing last month intended to end the lawsuits by essentially turning the company’s assets over to a trust that would be controlled by the plaintiffs.It is too early to know whether any of these settlement offers will stick. Although the federal judge presiding over the Cleveland trial, Dan Aaron Polster, has asked the CEOs of the three distributors plus Teva to appear Friday to discuss the settlement talks, I’m told that the trial is still likely to begin on Monday, as scheduled.Any settlement will also need approval from the cities and counties that have filed suits. They are deeply suspicious of any deal the states might cut because they remember the outcome of the tobacco litigation. In 1998, the tobacco companies agreed to pay $246 billion over 25 years to the states, but little of that money trickled down to cities and counties. Indeed, a minuscule amount went to anti-tobacco efforts; most of the money is now used to fill state budget gaps.Still, whether it happens next week or next year, the opioid litigation will almost surely end with the companies being sued spending billions to settle it. The stock market practically demands it: Share prices of all the companies that have made settlement offers in recent days have jumped. And continuing litigation drains and distracts a company.Here’s the problem, though. Whenever plaintiffs’ lawyers argue that companies have done bad things and need to pay up, they justify the demand for money by saying it will be used to solve the problem. But will it? In this case, I have my doubts.In an opioid case in Oklahoma a few months ago, a judge ruled that Johnson & Johnson should pay $572 million (later reduced by $107 million), which he calculated would cover opioid abatement services in Oklahoma for just one year. So point one: Ending the crisis will require more money than even Big Pharma can provide.Second, just throwing money at the problem is not going to solve it. States and cities will most likely take different approaches. Some will be better than others. But there is no clear plan coming from the federal government — or anywhere else — about what steps are needed to end the crisis. Until there is, more money is likely to be wasted than not.Third, chances are good that the settlement money will be used for things that have nothing to do with opioids. Again, tobacco in instructive: Settlement money was supposed to be earmarked for tobacco control programs, but in most states the politicians couldn’t resist grabbing it for other purposes.Earlier this summer, during a court hearing, Judge Polster said that “developing solutions to combat a social crisis such as the opioid epidemic should not be the task of our judicial branch.” It was the job, he said, of the executive and legislative branches.He’s right. But that’s just not the American way. In the U.S., when there is a problem with a product, our first instinct is to sue the corporation that made it. When the litigation is settled, money is transferred from shareholders to plaintiffs (and their lawyers). It may be a satisfying resolution, but it rarely solves the problem. To reference tobacco one more time, two decades after the tobacco settlement, 480,000 Americans still die from smoking each year.I suspect the same will be true of the opioid crisis. The companies will settle, the lawyers will pocket millions and the states will get the rest. And the crisis will continue.I’ve said it before, and I’ll no doubt say it again: There’s got to be a better way.To contact the author of this story: Joe Nocera at jnocera3@bloomberg.netTo contact the editor responsible for this story: Daniel Niemi at dniemi1@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog
    Reuters

    Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

    Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall. Teva did not immediately respond to a request for comment. Rantidine, a copycat of GlaxoSmithKline's Zantac, is being taken off the shelves after the U.S. Food and Drug Administration found "unacceptable" levels of a probable cancer-causing impurity in the drug.

  • Market Exclusive

    Market Morning: Chinese Aircraft Carriers, DUP Sours on Brexit Deal, Big Opioid Settlement

    Chinese Aircraft Carrier Factory Revealed This will probably annoy the Trump Administration. Reuters reports exclusively that high-resolution satellite images show that China is progressing in the construction of a full sized aircraft carrier and should be the first of several large vessels produced. The site is called the Jinagnan shipyard and the images were taken […]The post Market Morning: Chinese Aircraft Carriers, DUP Sours on Brexit Deal, Big Opioid Settlement appeared first on Market Exclusive.

  • Drug firms offer to settle U.S. opioid suits with $50 billion package: sources
    Reuters

    Drug firms offer to settle U.S. opioid suits with $50 billion package: sources

    The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse. Local governments seek funds to cover costs of services in their communities. Distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson & Johnson would pay $4 billion in cash, two people familiar with the matter told Reuters.

  • J&J Makes $4 Billion Opioid Offer as Distributors Seek Deal
    Bloomberg

    J&J Makes $4 Billion Opioid Offer as Distributors Seek Deal

    (Bloomberg) -- Johnson & Johnson has offered to pay $4 billion to settle all claims accusing the company of helping fuel the U.S. opioid epidemic, as part of a potentially larger deal involving drugmakers and distributors that could top $20 billion.J&J’s overture came on the heels of a proposal by distributors McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. to pay $18 billion to wipe out all opioid suits against those companies, according to people familiar with the proposal. The Wall Street Journal first reported the distributors’ offer Tuesday. The money would be paid out in annual $1 billion increments, according to the people, who asked not to be identified because the negotiations are private.J&J and the distributors -- which deliver the majority of prescription medications to U.S. pharmacies -- made the proposal in talks with a group of state attorneys general, the people said. The proposals came on the eve of the first federal trial in Cleveland over responsibility for the public-health crisis tied to opioids.Shares of J&J gained 2.2% at 10:38 a.m. in New York on Wednesday, while McKesson shares rose 7.4%, Cardinal rose 5.7% and AmerisourceBergen gained 6.4%.Teva Pharmaceutical Industries Ltd., another drug manufacturer targeted in the nationwide litigation, offered to give away more than $15 billion in generic drugs, including those that help fight opioid overdoses, to resolve all of its cases, said the people. That agreement would run over 10 years, the people said.Israel-based Teva’s shares rose 6.3% in New York on news of the settlement proposal. Teva’s bonds were among the top performers in the U.S. high-yield market on Wednesday, according to Trace bond trading data. The company’s 6% unsecured bonds rose more than 1.5 cents on the dollar to around 91.5.Other opioid manufacturers implicated in the federal trial, including Mallinckrodt and Endo, also rose in the wake of the news.If all the proposals are accepted, the Cleveland trial likely will be put off given that the three distributors and Teva are the main defendants, the people said. In the trial, two counties are seeking reimbursement for the hundreds of millions in tax dollars spent on the fallout from opioid addictions and overdoses.“As we’ve stated previously, we remain open to viable options to resolve these cases, including through settlement,” Ernie Knewitz, a J&J spokesman, said in an emailed statement.U.S.-based Teva spokeswoman Kelley Dougherty declined to comment on the proposed deal. AmerisourceBergen spokesman Gabriel Weissman and Brandi Martin, a Cardinal Health spokeswoman, also declined to comment. McKesson spokeswoman Sunny Rodriguez didn’t respond to requests for comment.Samantha Fisher, a spokeswoman for Tennessee Attorney Herbert Slatery III, didn’t respond to an emailed request for comment, sent after regular business hours. Slatery is one of the leaders of the negotiations.It’s the first time J&J has put serious money on the table to end its opioid liability, the people said. The drugmaker agreed earlier this month to pay $20.4 million to two Ohio counties to avoid a federal trial, but that didn’t extend to any other opioid claim. Some analysts have said it may take as much as $150 billion to resolve all the opioid cases on file.What Bloomberg Intelligence Says:Johnson & Johnson’s settlement of two opioid cases in Ohio, if reflective of a global settlement, is in-line with our expectation that it could pay up to $5 billion. The news, along with its lower-than-expected Oklahoma fine, may indicate J&J won’t have to contribute much more than others based on its ability to pay.\-- Sam Fazeli, senior pharmaceutical analystClick here to view the research“It’s very rare for J&J to do anything else other than litigate these kinds of cases to the bitter end,” said Carl Tobias, a University of Richmond law professor who teaches about mass torts. “I think investors are going to be very happy they are talking global settlement.”Tobias said an Oklahoma judge’s decision to hit J&J with $572 million in damages over its sales of opioid painkillers in that state may have sent J&J an unmistakable signal. That judge acknowledged Tuesday that he made a $107 million error in his damages ruling and cut the award to $420 million.“That ruling may have showed them that no matter where they try those cases, they are going to have trouble persuading judges and juries they shouldn’t be on the hook for the costs of the opioid crisis,” Tobias said.The distributors’ latest proposal is $8 billion higher than the $10 billion offer they made in August. The National Association of Attorneys General, the group sponsoring talks on behalf of more than 35 states, countered with a demand for $45 billion at the time.The drug distributors generate large amounts of cash that could be used to pay a settlement. In its 2019 fiscal year, San Francisco-based McKesson generated $4.04 billion from operations, according to data compiled by Bloomberg. In fiscal 2018, Cardinal brought in $2.77 billion and AmerisourceBergen $1.41 billion.QuickTake: The Opioid CrisisStates, cities and counties claim opioid makers, including J&J and Teva, downplayed the painkillers’ health risks and oversold their benefits through hyper-aggressive marketing campaigns. Distributors, considered to have the deeper pockets by plaintiffs’ lawyers, are accused of ignoring red flags about misuse of the painkillers and illegally flooding states with pills.For example, one pharmacy in Kermit, West Virginia -- population 400 -- received almost 5 million doses from McKesson between 2005 and 2006, records show. About 30 miles (50 kilometers) from Kermit, the company shipped more than 5.8 million doses to a pharmacy in Mount Gay -- population 1,800 -- between 2006 and 2014. Another 2.3 million doses went to a pharmacy three miles away.McKesson, Cardinal Health and AmerisourceBergen, along with other distributors, shipped a total of 76 billion pain pills over a six-year period starting in 2006, according to the U.S. Drug Enforcement Agency. The companies deny the governments’ allegations and have advanced dozens of legal and factual defenses, saying they complied with all state and federal laws.Teva has been grappling with billions in debt as well as thousands of opioid suits over its generic painkillers. Teva’s 2015 acquisition of Allergan Plc‘s generic business for $40.5 billion pushed the company’s debt load from $10 billion to $35 billion.Chief Executive Officer Kare Schultz, who stepped into his role in late 2017, is trying to right a company hurt by falling margins on generic drugs and rapidly declining sales in its best-selling Copaxone multiple-sclerosis drug. Last year, the drugmaker cut its net debt by almost $1 billion to $28.4 billion.Teva officials have told the attorneys generas’ lawyers that the company’s debt load leaves little free cash flow for an opioid settlement, the people said. That’s why it’s offering access to free Narcan, an overdose drug, the people said. In April, the U.S. Food and Drug Administration approved Teva’s request to start selling a generic version of Narcan, a nasal spray version of the opioid-overdose reversal agent Naxalone.In August, Teva officials set aside $646 million to help pay legal expenses related to its alleged role in the abuse of the addictive painkillers linked to tens of thousands American deaths annually. Those funds weren’t devoted to paying settlements.Teva’s bid to use the drugs-for-dismissal model to resolve its opioid liability may indicate the company could face bankruptcy if the proposal gets turned down, said Elizabeth Burch, a University of Georgia law professor who teaches about product-liability law.“I guess free drugs are better than nothing, but it’s not perfect,” Burch said in an interview. “The real question is whether the local governments want to keep this company out of bankruptcy by accepting this offer.”(Updates stock-price movements beginning in fourth paragraph)To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Zacks

    J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

    J&J (JNJ) comes up with encouraging third-quarter 2019 results.

  • Lilly Gets FDA Approval for New Oral Tablets for Migraine
    Zacks

    Lilly Gets FDA Approval for New Oral Tablets for Migraine

    Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

  • Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
    Zacks

    Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

    Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.98 in the latest trading session, marking a +0.14% move from the prior day.

  • Business Wire

    Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. A live webcast of the call will also be available on Teva's website at: http://ir.tevapharm.com.

  • AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
    Zacks

    AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

    The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study

  • Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
    Zacks

    Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

    Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

  • The Market Tells Opioid Drugmakers to Settle Up
    Bloomberg

    The Market Tells Opioid Drugmakers to Settle Up

    (Bloomberg Opinion) -- The markets are sending a message to drugmakers facing opioid litigation: Settle up.Johnson & Johnson late Tuesday announced its first legal settlement over the pharmaceutical giant’s alleged role in spurring the opioid crisis, a modest $20 million deal with two Ohio counties. The agreement will see it avoid a risky trial later this month and the company’s stock rose as much as 3.6% in early trading. J&J’s deal came a day after a report that drugmakers may use Purdue Pharma’s bankruptcy as a model for a broader settlement, news that briefly boosted smaller companies including Mallinckrodt PLC, Teva Pharmaceutical Industries Ltd, and Endo International PLC. The profusion of litigation, the size of the addiction crisis, and public fury have created a liability of unknown size that could take years to resolve. Thousands of lawsuits remain, and a global deal that resolves a big chunk of those suits will be challenging to negotiate. J&J’s settlement cracks the door, however, and investors want resolution. Getting something done and moving on should be a priority for drugmakers over pinching pennies.  Banding together could help ensure that no drugmaker would be left behind to fight through every lawsuit or face a potential liability disproportionate to its relative role in the crisis. It won’t be cheap, and it won’t be easy, but it would be worth the effort.A global settlement, even if it involves a substantial cash payout, would go a long way toward helping drugmakers move forward from the crisis, while investors would finally be able to put a number on the liability instead of fearing the uncertain result of every individual trial. A settlement also could reduce the risk of bankruptcy for indebted members of the group, cutting another asymmetric risk. As for the other side, the parties affected by the crisis should fight aggressively for a large settlement. The amount of money needed to combat the crisis and build a real treatment infrastructure in America demands it. Beyond that, it’s worth fighting for a figure large enough to deter the kind of behavior and negligence that allegedly spurred the crisis. That doesn’t mean they should disdain a global settlement and the idea of compromise. A broad deal may be governments' best avenue to get cash quickly so they can help people in need as soon as possible. Stretching the fight out may not result in a larger payout, and could result in some communities getting nothing. We’re still a long way from a significant deal; many states oppose even the single-company version of Purdue’s bankruptcy. Hopefully, both sides will realize the benefits of avoiding a multi-year battle and make further progress. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • JNJ moves to dodge opioid bullets, but other drug names face uncertainty
    Yahoo Finance

    JNJ moves to dodge opioid bullets, but other drug names face uncertainty

    Opioid litigation increasingly affecting credit outlooks for drug makers and distributors.

  • Business Wire

    Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.

  • Teva Announces Leadership Change in its Global Operations Group
    Business Wire

    Teva Announces Leadership Change in its Global Operations Group

    Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced today the retirement of Dr. Carlo de Notaristefani, and the appointment of Eric Drapé as Executive Vice President, Global Operations. Mr. Drapé will be based out of Teva’s global headquarters in Israel. "After more than seven years leading Teva Global Operations, Carlo de Notaristefani, will retire from Teva," said Kare Schultz, Teva's President and CEO.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.76 in the latest trading session, marking a -1.74% move from the prior day.

  • Opioid Makers Gain on View They’ll Use Purdue Deal as Model
    Bloomberg

    Opioid Makers Gain on View They’ll Use Purdue Deal as Model

    (Bloomberg) -- Makers of prescription painkillers are climbing higher after Dow Jones reported that the companies are looking to use Purdue Pharma LP’s bankruptcy as a model to settle their own lawsuits.Mallinckrodt Plc and Endo International Plc jumped Tuesday morning as Wall Street gauged what shape their settlements might take. The two, plus drugmaker Teva Pharmaceutical Industries Ltd., are facing similar claims related to their role in sparking the opioid crisis.Shares of Mallinckrodt and Endo rose by at least 10% while Teva gained a much as 7.1%. Mallinckrodt has shed more than 90% of its market value in the past year and Endo and Teva are down 78% and 66%, respectively.Companies that distributed opioids -- McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. -- edged higher as the Purdue idea may signal progress in resolving lawsuits.(Updates share movement in third, fourth paragraph)To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Mallinckrodt Up on Settlement Agreement With Ohio Counties
    Zacks

    Mallinckrodt Up on Settlement Agreement With Ohio Counties

    Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.

  • Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits -WSJ
    Reuters

    Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits -WSJ

    Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter. Five drugmakers battling the cases - Endo, J&J, Teva Pharmaceutical Industries Ltd , Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported citing a person familiar with the matter. OxyContin maker Purdue filed for bankruptcy protection in September, succumbing to pressure from more than 2,600 lawsuits alleging the company helped fuel the deadly U.S. opioid epidemic.

  • Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
    Zacks

    Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

    Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

  • Opioid Overdose Crisis in US Likely to Affect These 3 Stocks
    Zacks

    Opioid Overdose Crisis in US Likely to Affect These 3 Stocks

    Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.96 in the latest trading session, marking a -1.14% move from the prior day.

  • Mallinckrodt's StrataGraft Tissue Phase III Data Positive
    Zacks

    Mallinckrodt's StrataGraft Tissue Phase III Data Positive

    Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.

  • J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
    Zacks

    J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

    J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.